# Tolerogenic and pathologic interactions between ILCs and T cells in autoimmunity

> **NIH NIH F31** · WEILL MEDICAL COLL OF CORNELL UNIV · 2020 · $45,520

## Abstract

PROJECT SUMMARY
Autoimmunity and chronic inflammatory diseases develop as a result of a complex interplay of genetic,
environmental, and lifestyle factors that are unique to each individual. However, these diseases manifest in a
common immunologic response defined by a persistent hyper-responsiveness to self-tissues, environmental
antigens, or commensal microorganisms. Notably, recent genetic and experimental evidence demonstrate that
IL-17 producing CD4 T helper (Th17) cells are a major pathogenic cell type involved in the pathogenesis of
inflammatory bowel disease (IBD), multiple sclerosis (MS), and rheumatoid arthritis (RA). Despite these
advances, it remains poorly understood how Th17 cells are induced and regulated in the context of
autoimmunity. Recently my host laboratory defined that a related cell type of the innate immune system,
termed group 3 innate lymphoid cells (ILC3), play an essential tolerogenic role in the intestine by restraining
Th17 cell responses to commensal bacteria through antigen-presentation via major histocompatibility complex
class II (MHCII+ ILC3). In new preliminary data generated for this proposal, I now define that MHCII+ ILC3
functionally impact the progression of experimental autoimmune encephalomyelitis (EAE), an animal model for
T-cell mediated human multiple sclerosis (MS), and further test whether we can employ this tolerogenic
pathway to prevent EAE. The fundamental focus of this research proposal is to better define how ILC3/T cell
interactions occur and functionally impact the progression of autoimmunity to self-antigens. It is expected that
results from the two aims of this proposal will crucially define the role and therapeutic potential of modulating
interactions between ILC3s and CD4 T cells in the context of MS that could be extended to other forms of T
cell mediated autoimmunity.

## Key facts

- **NIH application ID:** 10017643
- **Project number:** 5F31AI138389-02
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** John Benjamin Grigg
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $45,520
- **Award type:** 5
- **Project period:** 2019-09-06 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10017643

## Citation

> US National Institutes of Health, RePORTER application 10017643, Tolerogenic and pathologic interactions between ILCs and T cells in autoimmunity (5F31AI138389-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10017643. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*